According to a World Health Organization (WHO) classification, gliomas are divided based on molecular dysfunctions and histopathology into WHO grade I gliomas (benign tumors with infrequent genomic alterations and long-term survival), grades II and III diffuse gliomas (characterized by the presence or absence of mutations in IDH, TERT, ATRX and copy number alterations of 1p, 19q, 7, and 10q) and grade IV glioblastoma, the most malignant tumor with numerous genomic alterations1,2. This evidence concerns the gene ATRX and glioma.